About Modis Therapeutics
Modis Therapeutics is a company based in Oakland (United States) founded in 2016 was acquired by Zogenix in August 2019. Modis Therapeutics has raised $30 million across 1 funding round from investors including Zogenix, Orbimed and F-Prime Capital. Modis Therapeutics operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Oakland, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Modis Therapeutics
Unlock access to complete
Software Development Team
219 people
Leadership Team
92 people
Head Team
57 people
Global Team
39 people
Senior Team
36 people
Operations Team
36 people
Product Management Team
34 people
Human Resources and Administration
22 people
Unlock access to complete
Funding Insights of Modis Therapeutics
Modis Therapeutics has successfully raised a total of $30M through 1 strategic funding round. The most recent funding activity was a Series A round of $30 million completed in October 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Modis Therapeutics
Modis Therapeutics has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include Zogenix, Orbimed and F-Prime Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations.
|
Locked | Locked | Locked | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Aceras Biomedical is focused on healthcare investment for medical innovations.
|
Locked | Locked | Locked |
Investor details for Modis Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Modis Therapeutics
Investment portfolio details for Modis Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Modis Therapeutics
Detailed financials for Modis Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Modis Therapeutics Comparisons
Peer comparison for Modis Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Modis Therapeutics
Modis Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
Detailed competitors of Modis Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Modis Therapeutics
Complete news archive for Modis Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Modis Therapeutics
Modis Therapeutics was founded in 2016 and raised its 1st funding round 2 years after it was founded.
Modis Therapeutics is headquartered in Oakland, United States. It is registered at Oakland, California, United States.
Modis Therapeutics is a funded company, having raised a total of $30M across 1 funding round to date.
Modis Therapeutics was founded in 2016 in Oakland, United States. Focus is placed on providing therapies for rare genetic diseases, particularly Thymidine kinase 2 deficiency, which causes mitochondrial dysfunction and impaired cellular energy production. Deoxynucleoside combination therapy is being developed to address mitochondrial DNA depletion disorders and restore cellular function in affected patients. Operations center on biotechnology research in the rare disease sector.
Modis Therapeutics's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Modis Therapeutics has 5 investors. Key investors include Zogenix, Orbimed, F-Prime Capital, Aceras Biomedical, and Osage University Partners.